Takotsubo syndrome is not so benign after all

  • Pelliccia F & al.
  • JACC Heart Fail
  • 2 Jan 2019

  • curated by Jenny Blair, MD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Long-term annual mortality after Takotsubo syndrome (TS) is 3.5%; just under 2% of patients die in the hospital.
  • Factors portending poor prognosis are a preceding physical stressor, older age, and acute atypical ballooning (global left ventricular stunning).
  • Prospective studies are needed.
  • Editorial discusses primary vs secondary TS, possible links to extracardiac conditions.

Why this matters

  • Also known as “broken heart syndrome,” TS has long been considered relatively benign, but recent studies challenge that notion.
  • Which acute-phase factors predict long-term prognosis have been unclear.

Key results

  • Mortality rate during index admission: 1.8% (95% CI, 1.2%-2.5%).
  • Median follow-up: 28 months.
  • Long-term annual mortality rate: 3.5% (95% CI, 2.6%-4.5%). 
  • Annual recurrence rate: 1.0% (95% CI, 0.7%-1.3%).
  • On meta-regression, factors associated with:
    • In-hospital mortality: physical stressor preceding illness;
    • Long-term mortality: older age, physical stressor, atypical ballooning; and
    • Recurrence: none.
  • Heart failure at presentation did not predict long-term mortality or recurrence.
  • Similar results on sensitivity analyses.
  • Most studies were high-quality, and publication bias was not detected.

Study design

  • Systematic review and meta-regression analysis of 54 observational studies with ≥6-month follow-up (n=4679).
  • Outcomes: in-hospital mortality, long-term mortality, recurrence rate.
  • Funding: None disclosed.

Limitations

  • Significant heterogeneity.
  • No comparisons to healthy or to post-acute coronary syndrome populations.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit